Henry James International Management Inc. Cellectis S.A. Transaction History

Henry James International Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$8.01 - $12.84 $275,183 - $441,118	-34,355 Closed	0 $0
Q3 2021 Oct 19, 2021	SELL	$11.94 - $16.09 $38,984 - $52,533	-3,265 Reduced 8.68%	34,355 $433,000
Q2 2021 Jul 30, 2021	BUY	$14.36 - $20.93 $359 - $523	25 Added 0.07%	37,620 $582,000
Q1 2021 Apr 19, 2021	BUY	$18.19 - $33.25 $683,853 - $1.25 Million	37,595 New	37,595 $760,000
Q2 2019 Jul 17, 2019	SELL	$14.6 - $20.6 $272,961 - $385,137	-18,696 Closed	0 $0
Q1 2019 Apr 22, 2019	SELL	$15.53 - $19.75 $262,767 - $334,170	-16,920 Reduced 47.51%	18,696 $343,000
Q4 2018 Feb 07, 2019	BUY	$15.58 - $28.41 $1,308 - $2,386	84 Added 0.24%	35,616 $593,000
Q3 2018 Nov 15, 2018	BUY	$25.99 - $30.6 $923,476 - $1.09 Million	35,532 New	35,532 $1 Million

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Henry James International Management Inc., based on Form 13F filings with the SEC.

Stay updated on Henry James International Management Inc. with notifications on news.